About the Company
Gemini Therapeutics is a clinical stage precision medicine company developing novel therapeutic compounds to treat genetically de?ned age-related macular degeneration (AMD). Gemini's lead candidate, GEM103, is a recombinant form of the human complement factor H protein (CFH), and is designed to address both complement hyperactivity and restore retinal health in patients with AMD. GEM103 is currently in a Phase 2a trial in dry AMD patients with a CFH risk variant. The company has generated a rich pipeline including recombinant proteins, gene therapies, and monoclonal antibodies.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $GMTX News
Bankrupt Crypto Lender Genesis to Give Back $2B of Virtual Currency As Part of Latest Gemini Settlement
Failed cryptocurrency lending firm Genesis will reportedly be returning 97% of crypto-assets from a customer program.
ARIX.L Regulatory News
About Gemini Therapeutics, Inc. Gemini Therapeutics is a clinical-stage precision medicine company previously focused on developing novel therapeutic compounds to treat genetically defined age ...
TG Therapeutics Inc TGTX
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
Gregg Beloff's Net Worth
Gregg Beloff does not have any significant net worth to report based on the numbers we have. This is based on reported shares across multiple companies, which include IMMUNOGEN INC, Gemini ...
Qualigen Therapeutics Inc Ordinary Shares QLGN
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
Fate Therapeutics, Inc.
Fate Therapeutics, Inc. engages in the development of programmed cellular immunotherapies for cancer and immune disorder. Its pipeline of products includes immuno-ocology candidates and immuno ...
Alaunos Therapeutics, Inc. (TCRT)
Best Response to TCR-T Best Response to TCR-T TCR-T Library Phase 1/2 trial achieved an 87% disease control rate of eight evaluable patients with metastatic, refractory solid tumors; TCR-T cell ...
Intellia Therapeutics, Inc.
Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms ...
Serina Therapeutics Appoints Dr. Simba Gill as Executive Chairman
Dr. Gill brings extensive leadership experience in transformative biotechnology platforms and drug development -HUNTSVILLE, AL, April 17, 2024 ...
Google's public release of Gemini 1.5 should build trust, Deutsche Bank says
Last week's announcement that Google (NASDAQ:GOOG) (NASDAQ:GOOGL) will public release its newest artificial intelligence ...
Vivos Therapeutics Inc (VVOS)
Vivos Therapeutics, Inc. (VVOS), a medical technology company specializing in the treatment of obstructive sleep apnea (OSA), held its Fourth Quarter and Full Year ...
Aligos Therapeutics, Inc. (ALGS) Just Flashed Golden Cross Signal: Do You Buy?
After reaching an important support level, Aligos Therapeutics, Inc. (ALGS) could be a good stock pick from a technical perspective. ALGS recently experienced a "golden cross" event, which saw its ...
Loading the latest forecasts...